New Blue Gene has achieved profitability and accelerated its ecological layout.
1. Deeply Engaged in Multi - Omics Research Services, Achieved High - Quality Profitability within One Year
Guangzhou Xinlan Gene was registered in October 2024 and officially started operation in February 2025. It was founded by Tan Baohua, a doctor from South China Agricultural University and a post - doctoral fellow at the Respiratory Research Institute of the First Affiliated Hospital of Guangzhou Medical University. The company focuses on the development and application of multi - omics technologies such as transcriptomics, epigenomics, and three - dimensional genomics, and has built a service system covering the entire process from experiment, sequencing, analysis to project conclusion.
As of now, the Xinlan Gene team consists of 13 people. It has completed a total project turnover of 4.16 million yuan and a net profit of 1.93 million yuan. It has delivered over 150 projects in total, processed more than 1,200 samples, and its services cover universities, hospitals, and research institutions across the country, demonstrating strong commercialization capabilities.
2. Self - Developed Automated Analysis Process and Self - Built Laboratory to Build Delivery Barriers
Xinlan Gene has gradually transitioned from outsourcing cooperation to a fully self - built laboratory model, establishing a standardized experimental management system and an automated bioinformatics analysis process. The self - developed analysis algorithm of the company has compressed the standard analysis cycle from 72 hours to within 15 hours, with only 3 hours of manual intervention, significantly improving delivery efficiency and data accuracy.
In terms of products, the company can develop more than 5 new products per month. It has already fully self - built 52 products and continues to deploy in cutting - edge technology sectors such as Mini - ATAC - seq and Mini - Cut&Tag, forming a differentiated technology barrier. At the same time, the new media matrix acquires customers efficiently, and the online channels contribute about 3.2 million yuan in turnover, becoming a stable growth engine.
3. Supported by Top - Tier Research Background, the Team Combines Academic and Industrial Capabilities
The founder, Tan Baohua, has a doctorate in animal genetics and breeding and post - doctoral experience at the State Key Laboratory of Respiratory Diseases. He studied under Academician Wu Zhenfang and Academician Zhong Nanshan, and specializes in epigenetic modification and early cancer screening technology. As the first author, he has published many high - level papers in top - tier journals such as Nature Genetics and Nature Communications, holds two authorized invention patents, and maintains research cooperation with top - tier teams such as those from the University of Chicago and Peking University.
The core team covers the entire chain of experiment, analysis, sales, and new media. The personnel structure is stable, and the division of labor is clear. It has the complete operational capabilities from technology R & D, project delivery to market expansion.
4. Future Layout: Three - Dimensional Genomics + Cloud Platform + Productization to Build an Industry - University - Research Ecosystem
Xinlan Gene plans to continuously upgrade in four major directions: First, build a three - dimensional genomics technology platform, deploy scHi - C and chromatin spatial structure analysis, and focus on precise cancer diagnosis and treatment; Second, develop an epigenetic cloud automated analysis system to achieve intelligent interpretation of multi - omics data and one - click report generation; Third, promote kit productization, launch reagents for m6A and cfRNA extraction, and optimize the "service + product" dual - drive structure; Fourth, deepen industry - university - research cooperation through joint laboratories and academic forums to expand market coverage and customer stickiness.
Relying on its technological advantages and a proven profit model, Xinlan Gene is upgrading from a scientific research service provider to a multi - omics technology ecosystem platform, continuously releasing value in the fields of basic life science research and clinical translation.